Ascendis Pharma A/S Reports Second Quarter 2017 Financial Results
(WorldNews Denmark)

- Clinical Pipeline Expands to Include TransCon PTH while Phase 3 Program for TransCon Growth Hormone Advances - - Conference Call Today at 8:00 a.m. Eastern Time - COPENHAGEN, Denmark, Aug. 18, 2017 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs in rare diseases, today announced financial results for the quarter ended June 30, 2017. `We are making excellent progress executing our Vision 20/20 strategic plan to establish Ascendis as a leading, integrated rare disease company,` said Jan Mikkelsen, Ascendis Pharma`s President and Chief Executive Officer. `Our phase 3...